PURPOSE: The objectives of the study were to estimate the incidence and clarify the clinicopathologic feature of sporadic microsatellite instability (MSI)-high (MSI-H) colon cancer. Furthermore, the role of MSI in colon cancer prognosis was also investigated. METHODS: Microsatellite status was identified by genotyping. The clinicopathologic differences between two groups (MSI-H vs. MSI-L/S) and the prognostic value of MSI were analyzed. RESULTS: From 1993 to 2006, 709 sporadic colon cancer patients were enrolled. MSI-H colon cancers showed significant association with poorly differentiated (28.3% vs. 7.2%, p = 0.001), proximally located (76.7% vs. 34.5%, p = 0.001), more high mucin-containing tumor (10.0% vs. 5.1%, p = 0.001) and female predominance (56.7% vs. 30.2%, p = 0.001). In multivariate analysis, MSI-H is an independent factor for better overall survival (HR, 0.459; 95% CI, 0.241-0.872, p = 0.017). CONCLUSIONS: Based on the hospital-based study, MSI-H colon cancers demonstrated distinguished clinicopathologic features from MSI-L/S colon cancers. MSI-H is an independent favorable prognostic factor for overall survival in colon cancer.
PURPOSE: The objectives of the study were to estimate the incidence and clarify the clinicopathologic feature of sporadic microsatellite instability (MSI)-high (MSI-H) colon cancer. Furthermore, the role of MSI in colon cancer prognosis was also investigated. METHODS: Microsatellite status was identified by genotyping. The clinicopathologic differences between two groups (MSI-H vs. MSI-L/S) and the prognostic value of MSI were analyzed. RESULTS: From 1993 to 2006, 709 sporadic colon cancerpatients were enrolled. MSI-H colon cancers showed significant association with poorly differentiated (28.3% vs. 7.2%, p = 0.001), proximally located (76.7% vs. 34.5%, p = 0.001), more high mucin-containing tumor (10.0% vs. 5.1%, p = 0.001) and female predominance (56.7% vs. 30.2%, p = 0.001). In multivariate analysis, MSI-H is an independent factor for better overall survival (HR, 0.459; 95% CI, 0.241-0.872, p = 0.017). CONCLUSIONS: Based on the hospital-based study, MSI-H colon cancers demonstrated distinguished clinicopathologic features from MSI-L/S colon cancers. MSI-H is an independent favorable prognostic factor for overall survival in colon cancer.
Authors: Jantine L Westra; Michael Schaapveld; Harry Hollema; Jelle P de Boer; Marian M J Kraak; Debora de Jong; Arja ter Elst; Nanno H Mulder; Charles H C M Buys; Robert M W Hofstra; John T M Plukker Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: R Kochhar; K C Halling; S McDonnell; D J Schaid; A J French; M J O'Connell; D M Nagorney; S N Thibodeau Journal: Diagn Mol Pathol Date: 1997-04
Authors: Shih-Ching Chang; Jen-Kou Lin; Shung Haur Yang; Huann-Sheng Wang; Anna Fen-Yau Li; Chin-Wen Chi Journal: Int J Cancer Date: 2006-04-01 Impact factor: 7.396
Authors: C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: J R Jass; K A Do; L A Simms; H Iino; C Wynter; S P Pillay; J Searle; G Radford-Smith; J Young; B Leggett Journal: Gut Date: 1998-05 Impact factor: 23.059
Authors: A Buckowitz; H-P Knaebel; A Benner; H Bläker; J Gebert; P Kienle; M von Knebel Doeberitz; M Kloor Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: Maria L Wikberg; Sofia Edin; Ida V Lundberg; Bethany Van Guelpen; Anna M Dahlin; Jörgen Rutegård; Roger Stenling; Ake Oberg; Richard Palmqvist Journal: Tumour Biol Date: 2013-01-18